2
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
3
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
pembrolizumab
567
Specimen Handling
487
Carboplatin
456
Magnetic Resonance Spectroscopy
442
Cyclophosphamide
418
Cisplatin
412
Radiotherapy
353
Gemcitabine
318
Bevacizumab
317
Paclitaxel
304
Biopsy
291
Drug Therapy
286
Blood Specimen Collection
249
Capecitabine
244
Oxaliplatin
242
fludarabine
238
Nivolumab
236
venetoclax
227
Injections
214
Docetaxel
209
Fluorouracil
204
Dexamethasone
187
Radiosurgery
182
Rituximab
162
Pemetrexed
160
Standard of Care
156
Surgical Procedures, Operative
148
durvalumab
146
atezolizumab
146
tislelizumab
140
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
gadoteridol
×
Clear all
NCT04373564
2026-01-22
ODYSSEY
Guerbet
Phase 4
Recruiting
2,076 enrolled